From Pharmexec News Today

Tracing biopharma’s innovation evolution—and, framed by COVID-19 and the med-tech boon, a look at four notable efforts focused on that one elusive constant: translational value. A trillion-dollar industry whose members once practiced “not-invented-here syndrome” with near-religious fervor have now, for the most part, embraced on a formal scale what critics long wanted it to do: Seek and find innovators. Don’t, they had said, let a project fail just because a critical widget for sa...